Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
A Prospective Multi-center Randomized Trial Assessing the Safety and Effectiveness of Biodegradable Polymer Target Release Rapamycin-Eluting STent vs. XIENCE V Everolimus-Eluting Stent for the Treatment of Coronary Artery Disease
Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
Listed as NCT01196819, this NA trial focuses on Coronary Artery Disease and remains completed. Sponsored by Shanghai MicroPort Medical (Group) Co., Ltd., it has been updated 10 times since 2010, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 5 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed NA
-
Feb 2019 — Aug 2019 [monthly]
Completed NA
-
Jun 2018 — Feb 2019 [monthly]
Completed NA
-
Mar 2018 — Jun 2018 [monthly]
Completed NA
Status: Unknown Status → Completed · Phase: PHASE3 → NA
-
Jan 2017 — Mar 2018 [monthly]
Unknown Status PHASE3
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai MicroPort Medical (Group) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .